Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV004874622 | SCV005511923 | uncertain significance | not specified | 2024-11-18 | criteria provided, single submitter | clinical testing | The p.I340T variant (also known as c.1019T>C), located in coding exon 1 of the TET2 gene, results from a T to C substitution at nucleotide position 1019. The isoleucine at codon 340 is replaced by threonine, an amino acid with similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. |
Labcorp Genetics |
RCV005061608 | SCV005722757 | uncertain significance | not provided | 2024-07-27 | criteria provided, single submitter | clinical testing | This sequence change replaces isoleucine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 340 of the TET2 protein (p.Ile340Thr). This variant is present in population databases (rs368403190, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with TET2-related conditions. An algorithm developed to predict the effect of missense changes on protein structure and function outputs the following: PolyPhen-2: "Benign". The threonine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |